BigHat Biosciences

BigHat Biosciences is a biotechnology company founded in 2019 and based in San Mateo, California.

The company focuses on designing safer and more effective antibody therapies using its proprietary MillinerTM platform, which integrates machine learning, synthetic biology, and automated high-speed wet-lab automation. BigHat aims to improve human health by simplifying the design of advanced antibody therapeutics for challenging diseases in oncology, inflammation, and immunology. As a Series B company, BigHat has raised over $100 million in funding, including a $75 million Series B round led by Section 32. The company has a pipeline of 10 therapeutic programs and collaborates with notable pharmaceutical partners such as AbbVie, Eli Lilly, Merck, and Amgen. With a team of approximately 80 to 112 employees, BigHat fosters a team-oriented and inclusive culture, emphasizing innovation in drug discovery and development.